Prostatic Neoplasms
Conditions
Brief summary
This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo. These rates will provide context for second primary malignancy incidence rates from the REASSURE study. Furthermore this study aims to provide further information about the documentation of bone metastases in Medicare data and the extent of use of only oral androgen deprivation drugs among patients with Medicare Part D coverage, as well as to estimate overall survival of the study population.
Detailed description
Xofigo (radium-223 dichloride) is an alpha-emitting pharmaceutical, which was approved for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The long-term safety profile of Xofigo is evaluated in the prospective REASSURE study, which estimates the incidence rates of second primary malignancies in patients with CRPC receiving Xofigo. To provide context on that, this retrospective study is conducted to estimate background rates of second primary malignancies among patients with CRPC similar to those who are treated with Xofigo.
Interventions
OTHERNot applicable for study
Provide external perspective on background second primary cancer incidence rates for REASSURE study.
Sponsors
RTI Health Solutions
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Enrolled in both Medicare Parts A and B for at least 1 year before the cohort entry date (minimum lookback period for comorbidities and treatments) * Primary site code of prostate cancer (International Classification of Diseases for Oncology, Third Edition \[ICD-O-3\] topography code C61.9) in SEER data * Surgical castration or androgen deprivation therapy after prostate cancer diagnosis; androgen deprivation therapy will be indicated by the use of any of the following drugs: abarelix, bicalutamide, buserelin, cyproterone, degarelix, diethylstilbestrol, estramustine, flutamide, gonadorelin, goserelin, histrelin, leuprolide, medroxyprogesterone, megestrol, nafarelin, nilutamide, polyestradiol, triptorelin * Evidence that prostate cancer was resistant to surgical castration or androgen deprivation therapy (castration-resistant prostate cancer), as indicated by starting one of the following second-line systemic therapies (cohort entry date): abiraterone, cabazitaxel, docetaxel, enzalutamide, mitoxantrone, or sipuleucel-T * Cohort entry date 01 January 2006 or later * Age 65 years or older in the US on the cohort entry date
Exclusion criteria
* Enrollment in an HMO (Health Maintenance Organization) in the year before the cohort entry date * Diagnosis of any cancer other than prostate cancer or nonmelanoma skin cancer on or before the cohort entry date * Any diagnostic code for metastases other than bone metastases or lymph node metastases on or before the cohort entry date * Any claim for treatment with Xofigo on or before the cohort entry date.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of second primary malignancy | Retrospective analysis between 1-Jan-2000 and 31-Dec-2013 |
| Incidence rates of skeletal-related events | Retrospective analysis between 1-Jan-2000 and 31-Dec-2013 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion with a history of bone metastasis at cohort entry | Retrospective analysis between 1-Jan-2000 and 31-Dec-2013 |
| Proportion who met the definition of castration based solely on Part D data | Retrospective analysis between 1-Jan-2000 and 31-Dec-2013 |
| Overall survival | Retrospective analysis between 1-Jan-2000 and 31-Dec-2013 |
Countries
United States
Outcome results
None listed